Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2011, Article ID 747835, 8 pages
http://dx.doi.org/10.1155/2011/747835
Research Article

Argan Oil Exerts an Antiatherogenic Effect by Improving Lipids and Susceptibility of LDL to Oxidation in Type 2 Diabetes Patients

1Lipoproteins and Atherosclerosis Research Laboratory, Faculty of Sciences Ben Msik, Casablanca, Morocco
2Laboratory of Biochemistry, Faculty of Sciences Ain Chock, Casablanca, Morocco
3Endocrinology and Nutrition, and Metabolic Diseases Department, University Hospital of Ibn Sina, Rabat, Morocco

Received 1 July 2011; Accepted 22 August 2011

Academic Editor: Jack R. Wall

Copyright © 2011 M. M. Ould Mohamedou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. G. Athyros, K. Tziomalos, A. Karagiannis, and D. P. Mikhailidis, “Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment,” Open Cardiovascular Medicine Journal, vol. 5, pp. 24–34, 2011. View at Google Scholar
  2. M. A. Tazi, S. Abir-Khalil, N. Chaouki et al., “Prevalence of the main cardiovascularriskfactors in Morocco: results of a national surveyin 2000,” Journal of Hypertension, vol. 21, pp. 897–903, 2003. View at Google Scholar
  3. L. Zhang, Q. Qiao, J. Tuomilehto et al., “Blood lipid levels in relation to glucose status in sevenpopulations of Asian origin without a prior history of diabetes: the DECODA study,” Diabetes/Metabolism Research and Reviews, vol. 25, no. 6, pp. 549–557, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. B Vergès, “Combination lipid therapy in type 2 diabetes mellitus,” Expert Opin Pharmacother, vol. 9, pp. 1393–1403, 2011. View at Google Scholar
  5. B. Verggès, “New insight into the pathophysiology of lipid abnormalities in type 2 diabetes,” Diabetes and Metabolism, vol. 31, no. 5, pp. 429–439, 2005. View at Google Scholar · View at Scopus
  6. D. D. Thomas, “Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters,” International Journal of Women's Health, vol. 3, pp. 87–97, 2011. View at Google Scholar
  7. A. D. Sniderman, “Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: alternatives and surrogates versus the real thing,” Diabetes Care, vol. 26, no. 7, pp. 2207–2208, 2003. View at Google Scholar · View at Scopus
  8. N. Sathavarodom and A. Boonyavarakul, “Apolipoprotein B level in patients with type 2 diabetes who achieved goal of low density lipoprotein cholesterol and non-high density lipoprotein cholesterol,” Journal of The Medical Association of Thailand, vol. 93, pp. 166–172, 2010. View at Google Scholar
  9. J. D. Brunzell, M. Davidson, C. D. Furberg et al., “Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the american college of cardiology foundation,” Journal of the American College of Cardiology, vol. 51, pp. 1512–1524, 2008. View at Google Scholar
  10. D. E. Barre, K. A. Mizier-Barre, O. Griscti, and K. Hafez, “No gender associated differences in LDL oxidation in response to a CuSO4 challenge in a population of Caucasians with well-controlled type 2 diabetes,” International Journal of Diabetes and Metabolism, vol. 17, no. 3, pp. 81–85, 2009. View at Google Scholar · View at Scopus
  11. K. Kulkarni, H. Tiwari, L. Moore, and S. Jones, “A novel approach to measure apolipoprotein B/apolipoproteinAI ratio using the vertical auto profile method,” Diabetes and Vascular Disease Research, vol. 4, p. 266, 2007. View at Google Scholar
  12. R. Frenais, K. Ouguerram, C. Maugeais et al., “High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study,” Diabetologia, vol. 40, no. 5, pp. 578–583, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Walldius and I. Jungner, “The apo B/apo AI ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy: a review of the evidence,” Journal of Internal Medicine, vol. 259, no. 5, pp. 493–519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Walldus, I. Jungner, A. H. Aastveit, I. Holme, C. D. Furberg, and A. D. Sniderman, “The apo B/apo AI ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk,” Clinical Chemistry and Laboratory Medicine, vol. 42, no. 12, pp. 1355–1363, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Nyström, “C-reactive protein: a marker or a player?” Clinical Science, vol. 113, no. 1-2, pp. 79–81, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Lu, Y. Yang, Z. Yang et al., “Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity,” Cardiovascular Diabetology, vol. 9, p. 92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. M. Krauss, “Lipids and lipoproteins in patients with type 2 diabetes,” Diabetes Care, vol. 27, no. 6, pp. 1496–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Khallouki, C. Younos, R. Soulimani et al., “Consumption of argan oil (Morocco) with its unique profile of fatty acids tocopherols, squalene, sterols, and phenolic compounds should confer valuable cancer chemo-preventive effects,” European Journal of Cancer Prevention, vol. 12, no. 1, pp. 67–75, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Berrada, A. Settaf, K. Baddouri, A. Cherrah, and M. Hassar, “Experimental assessment of antihypertensive and hypolipidemic effects of oil of Argan, Argania sideroxylon,” Therapie, vol. 55, no. 3, pp. 375–378, 2000. View at Google Scholar · View at Scopus
  20. H. Berrougui, A. Ettaib, M. D. Herrera Gonzalez, M. Alvarez De Sotomayor, N. Bennani-Kabchi, and M. Hmamouchi, “Hypolipidemic and hypocholesterolemic effect of Argan oil in Merionesshawi rats,” Journal of Ethnopharmacology, vol. 89, no. 1, pp. 15–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Berrougui, M. Alvarez de Sotomayor, C. Pérez-Guerrero et al., “Argan (arganiaspinosa) oil lowers blood pressure and impreves endothelial dysfunction in spontaneously hypertensive rats,” The British Journal of Nutrition, vol. 92, no. 6, pp. 921–929, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Drissi, J. Girona, M. Cherki et al., “Evidence of hypolipemiant and antioxydant properties of argan oil derived from the argan tree (arganiaspinosa),” Clinical Nutrition, vol. 23, pp. 1159–1166, 2004. View at Google Scholar
  23. A. Derouiche, M. Cherki, A. Drissi et al., “Nutritional intervention study with argan oil in man: effects on lipids and apolipoproteins,” Annals of Nutrition and Metabolism, vol. 49, no. 3, pp. 196–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Charrouf and D. Guillaume, “Argan oil: occurrence, composition and impact on human health,” European Journal of Lipid Science and Technology, vol. 110, no. 7, pp. 632–636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. E. Monfalouti, D. Guillaume, C. Denhez, and Z. Charrouf, “Therapeutic potential of argan oil: a review,” Journal of Pharmacy and Pharmacology, vol. 62, no. 12, pp. 1669–1675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Boukhobza and N. Pichon-Prun, “L’arganier ressource economiqueetmedicinale pour le Maroc,” Phytotherapie, vol. 27, pp. 21–26, 1988. View at Google Scholar
  27. W. Richmond, “Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum,” Clinical Chemistry, vol. 19, no. 12, pp. 1350–1356, 1973. View at Google Scholar · View at Scopus
  28. P. Trinder, “Enzymatic method of triglycerides,” Annals of Clinical Biochemistry, vol. 6, pp. 24–27, 1969. View at Google Scholar
  29. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  30. W. Becker, W. Rapp, H. G. Schenk, and K. Störiko, “Methodenzur quantitative Bestimmung von Plasma protein endurchImmunpräzipitation,” Zeitschrift für Klinische Chemie und Klinische Biochemie, vol. 6, pp. 113–122, 1968. View at Google Scholar
  31. J. Siedel, S. Schiefer, M. Rosseneu et al., “Method for routine determinations of apolipoproteins AI, AII and B in normo- and hyperlipemic sera compared with immunonephelometry,” Clinical Chemistry, vol. 34, no. 9, pp. 1821–1825, 1988. View at Google Scholar · View at Scopus
  32. N. Rifai and M. E. King, “Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum,” Clinical Chemistry, vol. 32, no. 6, pp. 957–961, 1986. View at Google Scholar · View at Scopus
  33. H. K. Naito, “Reliability of lipid, lipoprotein, and apolipoprotein measurements,” Clinical Chemistry, vol. 34, no. 8, pp. 84–94, 1988. View at Google Scholar · View at Scopus
  34. O. Senju, Y. Takagi, K. Gomi, N. Ishii, S. Mochizuki, and N. Ishii, “The quantitative determination of CRP by latex agglutination photometric assay,” Japanese Journal of Clinical Laboratory Automation, vol. 8, pp. 161–165, 1983. View at Google Scholar
  35. C. P. Price, A. K. Trull, D. Berry, and E. G. Gorman, “Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein,” Journal of Immunological Methods, vol. 99, no. 2, pp. 205–211, 1987. View at Google Scholar · View at Scopus
  36. S. Eda, J. Kaufmann, W. Roos, and S. Pohl, “Development of a new microparticle-enhanced turbidimetric assay for C- reactive protein with superior features in analytical sensitivity and dynamic range,” Journal of Clinical Laboratory Analysis, vol. 12, no. 3, pp. 137–144, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Jaffé, “Ueber den Niederschlag, welchen Pikrinsäure in normalem Harnerzeugt und übereineneue Reaction des Kreatinins,” Zeitschrift für Physikalische Chemie, vol. 10, pp. 391–400, 1886. View at Google Scholar
  38. D. L. Fabiny and G. Ertingshausen, “Automated reaction-rate method for determination of serum creatinine with the CentrifiChem,” Clinical Chemistry, vol. 17, no. 8, pp. 696–700, 1971. View at Google Scholar · View at Scopus
  39. H. Bartels and M. Böhmer, “Micro-determination of creatinine,” Clinica Chimica Acta, vol. 32, pp. 81–85, 1971. View at Google Scholar
  40. W. Sattler, D. Mohr, and R. Stocker, “Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence,” Methods in Enzymology, vol. 233, pp. 469–489, 1994. View at Publisher · View at Google Scholar · View at Scopus
  41. H. A. Kleinveld, H. L. M. Hak-Lemmers, A. F. H. Stalenhoef, and P. N. M. Demacker, “Improved measurement of low density lipoprotein Susceptibility to copper-induced oxidation: application of a Short procedure for isolating low density lipoprotein,” Clinical Chemistry, vol. 38, no. 10, pp. 2066–2072, 1992. View at Google Scholar · View at Scopus
  42. K. G. Alberti, P. Zimmet, and J. Shaw, “Metabolic syndrome,” Diabetic Medicine, vol. 23, no. 5, pp. 469–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Samane, R. Christon, L. Dombrowski et al., “Fish oil and argan oil intak differently modulate insulin resistance and glucose intolerance in a rat model of dietary induced obesity,” Metabolism, vol. 58, no. 7, pp. 909–919, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Keys, J. Anderson, and F. Grande, “Prediction of serum cholesterol response of man to change in fats in the diet,” The Lancet, vol. 270, no. 7003, pp. 959–966, 1957. View at Google Scholar · View at Scopus
  45. D. M. Hegsted, R. B. McGandy, M. L. Myers, and F. J. Stare, “Quantitative effects of dietary fat on serum cholesterol in man,” The American Journal of Clinical Nutrition, vol. 17, no. 5, pp. 281–295, 1965. View at Google Scholar · View at Scopus
  46. R. Takada, M. Saitoh, T. Mori et al., “Dietary gamma-linolenic acid enriched oil reduces body fat content and induces liver enzyme activities relating to fatty acid beta-oxidation in rats,” Journal of Nutrition, vol. 124, pp. 469–474, 1994. View at Google Scholar
  47. A. Nagyova, P. Haban, J. Klvanova, and J. Kadrabova, “Effects of dietary extra virgin olive oil on serum lipid resistance to oxidation and fatty acid composition in elderly lipidemic patients,” Bratislavske Lekarske Listy, vol. 104, no. 7-8, pp. 218–221, 2003. View at Google Scholar · View at Scopus
  48. T. Heinemann, G. Axtmann, and K. Von Bergmann, “Comparison of intestinal absorption of cholesterol with different plant sterol in man,” European Journal of Clinical Investigation, vol. 23, no. 12, pp. 827–831, 1993. View at Google Scholar · View at Scopus
  49. S. Khandelwal, I. Demonty, P. Jeemon et al., “Independent and interactive effects of plant sterols and fisch oil n-3 long-chain polyunsaturated fatty acids on the plasma lipid profile of mildly hyperlipideamic Indian adult,” The British Journal of Nutrition, vol. 102, no. 5, pp. 722–732, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. I. Demonty, R. T. Ras, H. C. M. van Der Knaap et al., “Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake,” Journal of Nutrition, vol. 139, no. 2, pp. 271–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Marangoni and A. Poli, “Phytosterols and cardiovascular health,” Pharmacological Research, vol. 61, no. 3, pp. 193–199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. K. A. Varady, A. C. St Pierre, B. Lamarche, and P. J. H. Jones, “Effect of plant sterols and endurance training on LDL particle size and distribution in previously sedentary hypercholesterolemic adults,” European Journal of Clinical Nutrition, vol. 59, no. 4, pp. 518–525, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. J. M. Malinowski and M. M. Gehret, “Phytosterols for dyslipidemia,” American Journal of Health-System Pharmacy, vol. 67, no. 14, pp. 1165–1173, 2010. View at Google Scholar · View at Scopus
  54. L. M. Lima, M. D. G. Carvalho, A. D. P. Sabino, A. P. L. Mota, A. P. Fernandes, and M. O. Sousa, “Apo B/apo A-I ratio in central and peripheral arterial diseases,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 51, no. 7, pp. 1160–1165, 2007. View at Google Scholar · View at Scopus
  55. J. Sierra-Johnson, V. K. Somers, F. H. S. Kuniyoshi et al., “Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome,” The American Journal of Cardiology, vol. 98, no. 10, pp. 1369–1373, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Fuhrman, A. Lavy, and M. Aviram, “Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation,” The American Journal of Clinical Nutrition, vol. 61, no. 3, pp. 549–554, 1995. View at Google Scholar · View at Scopus
  57. I. Jialal, C. J. Fuller, and B. A. Huet, “The effect of α-tocopherol supplementation on LDL oxidation. A dose-response study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 2, pp. 190–198, 1995. View at Google Scholar · View at Scopus